What tirzepatide already delivers Tirzepatide has done the thing all drug candidates are eventually judged on
While the acute nature of our design prevents us from making definitive statements on hypertrophic outcomes and load, our data suggest a potential preferential anabolic response to HL RE as exhibited by the observed load-mediated increase in AR-DNA binding
They vary in their duration, formulation and other features
[DOI] [PubMed] [Google Scholar] 195.Leiter LA, Carr MC, Stewart M, Jones-Leone A, Scott R, Yang F, Handelsman Y
Doses per vial formula Number of doses = Total vial volume in ml x Concentration in mg per ml / Weekly dose in mg Or expressed differently: Total mg in vial / Weekly dose in mg = Number of weekly doses Practical examples 5 mg/ml, 1 ml vial (5 mg total): At 0.25 mg/week: 5 / 0.25 = 20 doses (20 weeks supply) At 0.5 mg/week: 5 / 0.5 = 10 doses (10 weeks supply) At 1.0 mg/week: 5 / 1.0 = 5 doses (5 weeks supply) At 2.4 mg/week: 5 / 2.4 = ~2.1 doses (roughly 2 weeks supply) 5 mg/ml, 2 ml vial (10 mg total): At 0.25 mg/week: 10 / 0.25 = 40 doses (40 weeks supply) At 1.0 mg/week: 10 / 1.0 = 10 doses (10 weeks supply) At 2.4 mg/week: 10 / 2.4 = ~4.2 doses (roughly 4 weeks supply) 2.5 mg/ml, 1 ml vial (2.5 mg total): At 0.25 mg/week: 2.5 / 0.25 = 10 doses At 0.5 mg/week: 2.5 / 0.5 = 5 doses At 1.0 mg/week: 2.5 / 1.0 = 2.5 doses Keep in mind that syringe dead space (the medication trapped in the needle hub) reduces your effective yield by approximately 3 to 7 units per injection
However, severe bruising, spreading discoloration, or bruising lasting more than two weeks warrants a call to your provider to rule out underlying bleeding disorders or injection technique issues
